Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Iron Mountain Inc (IRM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Iron Mountain Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Iron Mountain Inc trades at $114.47 (market cap $34.44B). The key difference: Iron Mountain Inc is far larger — about 7.7× ACADIA Pharmaceuticals Inc.'s market cap, and Iron Mountain Inc pays a 2.99% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | IRM | |
|---|---|---|
Market Cap | $4.49B | $34.44B |
Sector | Health | Real Estate |
52-Week High | $28.06 | $133.06 |
52-Week Low | $20.06 | $78.86 |
Enterprise Value | $3.69B | $53.57B |
Dividend Yield | — | 2.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Iron Mountain (IRM) trades at $115.75, down 1.2% on the day, with strong recent earnings beats and a bullish analyst consensus of $138.67 price target. The stock shows technical bearish signals despite positive momentum news, while fundamentals reveal modest revenue growth to $6.90B in 2025 but declining net margins to 3.76%. Recent debt offerings of $1.5B highlight capital strategy moves amid high leverage.
Outlook remains cautiously optimistic given earnings outperformance and industry tailwinds, but risks include elevated debt levels and margin pressure. The stock offers growth potential with a 65% buy rating from analysts, though investors should weigh technical weakness against fundamental resilience in the information services sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →
